RM-718 RM-718 is a cyclic heptapeptide developed by Rhythm Pharmaceuticals using setmelanotide as a template, with a focus on increasing MC4R potency and selectivity while limiting activity on MC1R to reduce skin pigmentation effects for once-weekly injection ( Figure 2 ) (130)
Dhawan P, Singh AB, Ellis DL, Richmond A
These drugs include: Semaglutide (Wegovy, Ozempic) Tirzepatide (Mounjaro) Liraglutide (Saxenda) Common GLP1 side effects: Nausea Vomiting Diarrhoea or constipation Bloating Stomach pain Headaches Fatigue In the STEP 1 trial, participants using semaglutide 2.4 mg (Wegovy) reported the following during the first weeks: Nausea (44.2%) Diarrhoea (29.5%) Vomiting (24.2%) Constipation (23.4%) Most symptoms subsided after the dose-titration phase
Azitra Inc has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S
Mitochondrial disease in autism spectrum disorder patients: a cohort analysis